EUVIMEDEUVIMED entdecken
Crossref

Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer

X. Chen, D. Wang, Q. Li, F. Fan, W. Liu, W. Xi, L. Zhou, L. Xu, M. Li, J. Xiang, Z. Zhang

European Journal of Cancer · 2026-11 · 248 · 117529

DOI: 10.1016/j.ejca.2026.117529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von X. Chen und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Chen, X., Wang, D., Li, Q., Fan, F., Liu, W., Xi, W., Zhou, L., Xu, L., Li, M., Xiang, J., & Zhang, Z. (2026). Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer. European Journal of Cancer, 248, 117529. https://doi.org/10.1016/j.ejca.2026.117529

Vancouver

Chen X, Wang D, Li Q, Fan F, Liu W, Xi W, et al. Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer. European Journal of Cancer. 2026;248:117529. doi:10.1016/j.ejca.2026.117529

BibTeX
@article{Chen2026,
  author = {Chen, X. and Wang, D. and Li, Q. and Fan, F. and Liu, W. and Xi, W. and Zhou, L. and Xu, L. and Li, M. and Xiang, J. and Zhang, Z.},
  title = {Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117529},
  doi = {10.1016/j.ejca.2026.117529}
}
Kostenlos starten →